Young Blood Transfusions (alternative to Ambrosia in Mexico)
Please Note: The FDA prohibits this procedure in the United States & we are not able to offer this procedure here. Please contact us for more information on procedures available in Mexico.
Our Young Blood Transfusions are quickly becoming a popular medical procedure & Ambrosia Alternative Therapy that specifically transfers young blood cells and plasma from a young person into an older person. The sole intention and goal is to create increased energy and trigger significant rejuvenating factors. A fountain of youth of sorts.
Singular Biotech is a Los Angeles biotech company that specializes in an alternative to Ambrosia young blood transfusions and plasma therapy & treatments. We proudly have locations nationally and abroad. Our innovative biotechnology company has expanded to include San Diego, Mexico, India & Thailand.
While “ambrosia” plasma treatments and young blood transfusions are still being researched, those that have been fortunate enough to step into the unknown and reaped the benefits. Young Blood Transfusions reverse the aging process and leave your entire biological makeup reinvigorated.
Ambrosia Young Blood Transfusions. The Latest Anti-Aging Innovation
Those that have ponied up the price tag for ambrosia plasma treatments or young blood transfusions have likened it to what Benjamin Button felt like. The aging in reverse process is so significant that patients experience heightened senses, added strength and a complete overhaul of their overall health.
Singular Biotech has mastered the process of young blood transfusions of younger plasma into older patients.
In the Ambrosia plasma and young blood transfusion trial, roughly 80 participants with a median age of 60 had their blood tested for around 100 different biomarkers before receiving a single ambrosia transfusion, and then again a month later. “On average, patients had 21% fewer carcinoembryonic antigens, a compound associated with lung, colon, and ovarian cancer; 10% fewer apolipoproteins, associated with heart disease; and 20% fewer amyloid plaques, associated with Alzheimer’s.”
Young Blood is Brain Fuel
Popular ideas like taking the blood of the young to revive the sick are supported by scientific evidence but are rife with hype. Scientists may now have two new proteins to explain how transfusions work.
According to New Scientist, Stanford University scientists took blood from two mice groups — one was aged two weeks and the other was 12 to 15 months. They then applied it to human brain stem cells. The blood of the younger group boosted neural development more than the older ones, which lends weight to the notion of medical vampirism.
Home-Grown Young Blood & Plasma Transfusions
These transfusions can be revitalized by this research. According to the study published in PNAS, two proteins found in younger mouse blood, THBS4 (SPARCL1), lab-grown neurons grew more branches and formed twice as many connections. These factors indicate healthy and higher neural development.
But that doesn’t mean that the clinics out there claiming that young blood transfusions have medical benefits — a dubious assertion, according to the FDA — were right. Young blood transfusions are different from a pile of neurons. They can be cultured in a petri plate, but they don’t have the same quality as a human brain. This is why clinical experimentation is so important.
The Treatment of Aging Diseases with Young Blood Transfusions
This article has been cited by other articles in PMC.
Reports began to surface that young mice were able to give their blood to older mice around 15 years ago. This seemed to reverse the clock on the aging process for the old rodents. Older mice had signs of brain and muscle regeneration, as well as improved cognitive and physical performance. This discovery was made after other experiments, which resurrected parabiosis (a macabre technique that dates back to the mid-1800s). Parabiosis, which is similar to science fiction, involves the joining of old and young mice in order to share a circulatory system.
Parabiosis was first used by scientists to study how conjoined organisms (like twins) affect one another. They wanted to find out if molecules in bodily fluids could affect the physiology of the others. Parabiosis was abandoned after a decline in interest. It returned to the forefront in 2005 when scientists at Stanford University used the technique to address questions about tissue regeneration in older animals. Parabiosis was performed in mice to determine if this was due to changes in the cells themselves or their environment.
Scientists and the general public were both intrigued by the idea of a ‘elixir for youth’ after the 2005 study was published. Ambrosia, a California-based startup, began selling transfusions made of young plasma, the liquid component of blood, for $8,000 per liter in 2017. Despite the fact that there were no clinical trials to prove this treatment safe and effective in humans, Ambrosia was headquartered in Monterey. However, excitement soon became dampened by concerns about a dystopian future that would require the compulsory harvesting of blood from the young in order to support the elderly. Bioethics experts dismissed the scenario as science fiction.
The US Food and Drug Administration released a statement in February stating that plasma transfusions from young donors are not clinically proven to be beneficial. Credit: Ruchuda Boonplien/Shutterstock.
In February, concerned about premature application in humans based on findings in mice, the US Food and Drug Administration cautioned against young plasma transfusions, noting that they have “no proven clinical benefit” for age-related or other diseases in humans. Ambrosia also announced that it would cease transfusions the day after the FDA issued its statement. Now, the start-up has completely closed shop, Business Insider reports.
Researchers are now taking a more measured approach to young blood after the initial excitement. Researchers are not trying to reverse aging. Instead, they are identifying molecular factors that cause the changes in parabiosis experiments. This will allow them to target specific diseases related with aging such as Alzheimer’s disease or age-related maculardegeneration. Eric Verdin, CEO at the Buck Institute for Research on Aging, says that it is very difficult to conduct a clinical trial for aging. Researchers believe that a targeted approach to practical treatment could be more effective and faster than transfusing patients with fresh blood.
Verdin explains that the relative abundance of aging factors and regenerative elements in our bodies changes with age. At birth, our blood contains more regenerative factors–like oxytocin, which has been shown to rejuvenate skeletal muscle stem cells in mice–than aging factors. As we age, the balance shifts in favor of aging factor, such as eotaxin. This protein is thought to be involved in systemic inflammation and other age-related diseases. Regenerative factors increase our ability to repair and maintain tissue function and structure, while aging factors decrease it.
Researchers can use parabiosis to study mice and identify regenerative factors. They can compare the levels protein in blood of older mice with their new partners. Researchers say that the procedure is simple and less technical than giving blood transfusions to mice. Parabiosis results in mice experiencing rejuvenating effects.
Neurogenesis, the growth of new cells, is one of the many biological functions that decreases as we age. Researchers like Saul A. Villeda, a neuroscientist at the University of California in San Francisco, believe parabiosis experiments might help them identify factors that encourage neuronal growth. These molecular factors could lead to treatment for age-related cognitive decline and other neurological diseases. Villeda and his colleagues looked for stem-cell-related factors in mice that rose after parabiosis, because stem cells play a role in the growth of new tissue. They first scanned hippocampal neurons, ones in the brain’s center for learning and memory. The only one that significantly increased was Tet2, an enzyme that chemically tags genes with a hydroxymethyl group, altering their expression. The team found that these tagged genes play an important role in the development of neurons.
The results of parabiosis experiments, which connect the circulatory systems in old and young mice, have shown that there are regenerative factors within young blood. Credit: C&EN/Adapted by Villeda group.
Researchers found that Tet2 levels in hippocampi of mice and chemical tags that were added by the enzyme decreased with age, but increased in parabiosis-treated mice. Researchers found that neuronal growth declined in young adult mice when they blocked Tet2 activity in their hippocampi. This led to poor performance on learning and memory tests. The researchers increased Tet2 levels in mature adult mice. Neurogenesis returned to the same levels as in younger mice and memory was improved. Villeda and his colleagues are now identifying which neurons Tet2 affects, which could reveal which memory types the enzyme affects.
Thomas C. Sudhof, a molecular and cell physiologist at Stanford University, and Kathlyn J. Ga, a postdoctoral researcher in his lab are currently identifying molecules that promote synapses. These structures allow neurons to communicate with their neighbors. As we age, our ability to function as synapses decreases. The duo observed that synapses formed more frequently between neurons in young blood serum than in older blood serum. Two proteins–THBS4 and SPARCL1–appeared at higher levels in young serum. They were added to cultured neurons in Petri dishes, which boosted synaptic growth. Sudhof and Gan are now trying to identify the receptors that bind THBS4 or SPARCL1 on neurons and explore whether boosting synapse growth might be able to counter the loss of synapses, which is a common symptom of neurodegeneration. Regenerative factors have been shown to be effective in restoring cognitive function and neuron growth to younger levels in mice.
The Birth of Blood Vessels
Another research team is focusing on the potential implications of young blood for blood vessel formation. Alzheimer’s disease, and many other diseases of aging, can cause abnormalities in blood vessel formation. Alkahest, a San Carlos biotech company, has made investments in studying eotaxin. It is a hormone that increases with age. Alkahest is particularly interested in how eotaxin affects age-related macular disease (AMD). A abnormal growth of blood vessels in AMD is caused by fluid seeping into the retina. This can lead to blindness. Eotaxin helps promote the formation of blood vessels when it binds with a receptor on the blood vessels.
Alkahest created AKST4290 to reduce abnormal choroidal blood vessels growth. The firm recently reported Phase IIa clinical trial results showing that AKST4290 improved visual acuity in patients with previously untreated AMD. Elizabeth Jeffords is chief commercial and strategic officer at Alkahest. She believes that AKST4290, which is an oral medication could have “really significant” results. This is because doctors typically inject a standard drug therapy into the eyes to treat AMD. However, this is a more risky and invasive method of delivery.
Elevian is another biotech company that invests in GDF11, a protein that can be used to combat age-related diseases. GDF11, like AKST4290 is involved with blood vessel growth.
The founders of Elevian confirmed that GDF11 levels increased in parabiosis-treated mice. The firm’s researchers then administered GDF11 to mice and observed blood vessel growth throughout the brain. They also noticed neuronal growth in the subventricular and subgranular areas of the brain. Researchers believe that GDF11 stimulates neurogenesis by stimulating the cells that line blood vessels to release factors that promote neuron formation. Lee Rubin, Elevian cofounder, says that GDF11 appears to increase neurogenesis and also enhance brain blood supply.
The density of synapses in cultured neurons from humans is increased by the proteins THBS4 and SPARCL1. Credit: Courtesy of Kathlyn Gan/Proc. Natl. Acad. Sci. U.S.A.2019, DOI: 10.1073/pnas.1902672116.
This hypothesis is not supported by everyone. However, attempts to replicate Elevian’s findings have shown that GDF11 could actually impair neurogenesis. For instance, a 2018 study conducted by researchers at the Chinese Academy of Medical Sciences and Peking Union Medical College found that GDF11 promoted programmed cell death and maturation in neural stem cells, and prevented them from migrating, which they need to do to repair damaged tissue. Consistent with Elevian’s findings, though, researchers at Jiaotong University, Fudan University, and other institutions reported that GDF11 rejuvenated the brain’s vasculature in mice.
Elevian CEO Mark Allen, cofounder of Elevian, believes GDF11 still holds promise. The company continues to look for suitable applications and ways to extend its life expectancy.
The Complexity of the Picture
Others who research aging believe that the young blood may be able to point us to other regenerative factors that can help with disease. Irina Conboy, University of California, Berkeley, said that research to slow down or stop aging is more complicated than looking for regenerative genes in blood. The 2005 study on the rejuvenating effects of parabiosis, done by Conboy while she was a postdoc at Stanford and her colleagues, helped catapult interest in the therapeutic potential of young blood. Conboy points out that parabiosis is a process in which animals share not only their circulatory system, but also their immune, and organ systems. This makes it difficult to exclude the influence of these systems on rejuvenation or aging.
Conboy’s lab created a parabiosis-like method that allows mice to only exchange blood ten years after the study was completed. The researchers tested the technique on young and old mice and found that the younger mouse showed negative effects when it had equal amounts of old and young blood. Old blood drastically decreased hippocampal neuron generation, learning and agility, and liver regeneration in young mice. Old mice with young blood showed no benefits in cognition, agility or generation of hippocampal neurons. The secret to slowing down aging is not in increasing rejuvenating factors, but in blocking factors found in old blood that promote ageing–ones that inhibit tissue maintenance and repair.
Conboy and his team are just beginning to find these age-related factors. They recently turned their attention to TGF-b, which is a protein that rises with age. In a study published in August, they showed that pharmacologically normalizing the activity of the TGF-b pathway, which is elevated in old age, while adding the rejuvenating factor oxytocin improves muscle regeneration, enhances hippocampal neuron growth, and boosts cognition, among other effects, in old mice. Conboy believes that normalizing multiple factors will be necessary to prevent aging. She says, “You can’t write or play a whole symphony using one instrument.” “No single molecule can stop ageing.”
Verdin at the Buck Institute doesn’t expect to see any combination therapies for quite some time. Researchers are still trying to determine the individual factors. It’s easier to get FDA approval for single factor therapies than it is for combination therapies.
Although individual treatments that target specific conditions might seem more appealing than the dystopian scenario of forced blood donation, they still pose ethical questions. According to Craig M. Klugman, DePaul University’s bioethicist, most wealthy people would not have access to these treatments, as they are unlikely to be covered under insurance or Medicare. This could lead to a more healthy, longer-lived wealthy group and a lower-income middle and lower-income class. Klugman notes that the benefits of improving the lives and resources of the majority, which we can do already, “outweigh the science fiction dreams of just a few.”
Verdin states that aging with its many chronic diseases and associated health problems also takes a toll on society. Verdin doesn’t think the effort to help people live longer, healthier lives is any different from medical advancements over the past century which have increased the average life expectancy. He says, “One could argue, ‘You’re not living enough.'” Verdin disagrees. He sees what most people now consider the end of life as “the beginning of the human adventure.” A slow, meticulous search for molecules to restore our ability maintain and repair tissues – though perhaps not as flashy as a young-bloodelixir – may make this adventure possible.
Reverse the Age of Your Cells, Ambrosia Alternative Young Blood Treatments
As we age, though, cells start to get sloppy. The proteins they make may be misshape. Not so badly that they stop working, but bad enough to start limiting other cell function. Eventually, you get buildups of enough bad proteins that cause the disease—like the Alzheimer’s amyloid plaques.
Despite all of the skepticism, Singular Biotech stands behind this innovative service and science. It is well known that technologies are far outpacing that of proper review boards and have outgrown the slow process of proper panel testing. But the results speak for themselves. So far, there is no evidence to discount this as a rock-solid rejuvenation technique that can add years to your life, improve cognition and may even make your skin look 10x younger.